A quicker regulatory process and strong clinical science for years have made Europe an early launching pad for many US medical device start-ups, and Krauth Medical, Germany's leading distributor, a natural partner. For Krauth itself, continued cost pressures on the German health care system necessitated the need for a strategic overhaul a couple of years ago. The company has shed some long-standing businesses and gotten into some new areas, including spine and aesthetic surgery.
David Cassak
For much of the 1990s and early 2000s, for many US-based medical device start-ups, particularly cardiovascular companies, the first stop...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG
Understand who’s influencing access decisions and how pharma can engage strategically across the continent.
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
